The mitral valve disease therapeutics market valued for $607.74 million in 2022 and is estimated to reach $803.44 million by 2032, exhibiting a CAGR of 2.8% from 2023 to 2032. Mitral valve disease is a condition that affects the mitral valve, which is located between the left atrium and left ventricle of the heart. The mitral valve helps regulate blood flow through the heart, ensuring that blood flows from the left atrium to the left ventricle. Common mitral valve disease Includes conditions such as mitral valve regurgitation, mitral valve stenosis, and mitral valve prolapse. In mitral valve regurgitation, the valve does not close properly, allowing blood to flow back into the left atrium.
Further, in mitral valve stenosis, the valve becomes narrowed, making it difficult for blood to flow through. In mitral valve prolapse, the valve's leaflets bulge back into the left atrium when the heart contracts, which can sometimes cause a backflow of blood. Mitral valve diseases Include symptoms such as fatigue, heart murmur, irregular heartbeat, shortness of breath, and others. Thus, appropriate medications such as beta blockers, diuretics, anticoagulants, and others are used to manage symptoms and improve heart function.
The major factor driving the growth of the mitral valve disease therapeutics market is Increase in prevalence of mitral valve conditions. There has been an Increase in the number of patients diagnosed with mitral valve diseases such as mitral regurgitation, mitral prolapse, and mitral stenosis. For instance, Journal of Clinical Medicine 2022, stated that, mitral regurgitation is the second most common valvular heart disease in Europe and the most common in the U.S., with a prevalence of 9.3% in the population aged over 75 years. Thus, rise in prevalence of mitral valve conditions results in demand for therapeutics and propels the market growth.
Further, mitral valve disease can be caused by various factors, such as rheumatic fever and congenital heart defects. Rheumatic fever is an inflammatory disease that can occur after a streptococcal infection, leading to inflammation that can spread to the heart, causing damage to the heart valves, Including the mitral valve. Thus, this damage can lead to mitral valve disease, which can cause symptoms such as shortness of breath, fatigue, chest pain, and heart palpitations. In addition, congenital heart defects are structural abnormalities that are present at birth. Some congenital heart defects can affect the function of the mitral valve, leading to mitral valve disease. Thus, to manage the symptoms of mitral valve disease, therapeutics such as beta blockers, diuretics, and calcium channel blockers are prescribed, thereby driving the growth of the market.
Furthermore, rise in mitral valve replacement procedures and adoption of therapeutics is expected to propel the market growth. For instance, anticoagulants are commonly used to manage mitral valve disease and prevent blood clots, which can lead to serious complications such as stroke. Thus, rise in adoption of anticoagulants drives the market growth.
Further, rise in the Incidence of mitral valve diseases can be attributed to several factors, such as aging population and Increase in risk factors such as high blood pressure, diabetes, and obesity. As the population ages, the risk of developing mitral valve disease Increases. This is because the valve can become damaged or weakened over time, making it more prone to malfunction. In addition, the rise in risk factors such as high blood pressure and obesity can Increase the risk of developing mitral valve disease. Moreover, rise in awareness of mitral valve diseases among patients and healthcare professionals has led to earlier diagnosis and treatment, driving demand for medical interventions. Governments around the world are investing in research and development of new treatments for mitral valve disease, which has led to the development of novel therapeutics.
In addition, Increased awareness about the symptoms and risk factors associated with mitral valve disease has led to more people seeking medical treatment for the condition, which has further driven the growth of the market. However, availability of other treatment options for mitral valve disease is expected to restrain the growth of mitral valve disease therapeutics market. There are several alternative treatment options available for mitral valve disease, such as surgical interventions and transcatheter procedures. These alternative options may be preferred by some patients or may be recommended by healthcare providers based on individual patient needs, thus restraining the growth of market.
The global mitral valve disease therapeutics market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into beta blockers, diuretics, anticoagulants, and others. As per age group, the market is categorized into below 55 years and above 55 years. According to distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global mitral valve disease therapeutics market are Zydus Lifesciences Limited, Pfizer Inc., Bayer AG, Novartis AG, Viatris Inc., Alembic Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Limited, and Sanofi.
Further, in mitral valve stenosis, the valve becomes narrowed, making it difficult for blood to flow through. In mitral valve prolapse, the valve's leaflets bulge back into the left atrium when the heart contracts, which can sometimes cause a backflow of blood. Mitral valve diseases Include symptoms such as fatigue, heart murmur, irregular heartbeat, shortness of breath, and others. Thus, appropriate medications such as beta blockers, diuretics, anticoagulants, and others are used to manage symptoms and improve heart function.
The major factor driving the growth of the mitral valve disease therapeutics market is Increase in prevalence of mitral valve conditions. There has been an Increase in the number of patients diagnosed with mitral valve diseases such as mitral regurgitation, mitral prolapse, and mitral stenosis. For instance, Journal of Clinical Medicine 2022, stated that, mitral regurgitation is the second most common valvular heart disease in Europe and the most common in the U.S., with a prevalence of 9.3% in the population aged over 75 years. Thus, rise in prevalence of mitral valve conditions results in demand for therapeutics and propels the market growth.
Further, mitral valve disease can be caused by various factors, such as rheumatic fever and congenital heart defects. Rheumatic fever is an inflammatory disease that can occur after a streptococcal infection, leading to inflammation that can spread to the heart, causing damage to the heart valves, Including the mitral valve. Thus, this damage can lead to mitral valve disease, which can cause symptoms such as shortness of breath, fatigue, chest pain, and heart palpitations. In addition, congenital heart defects are structural abnormalities that are present at birth. Some congenital heart defects can affect the function of the mitral valve, leading to mitral valve disease. Thus, to manage the symptoms of mitral valve disease, therapeutics such as beta blockers, diuretics, and calcium channel blockers are prescribed, thereby driving the growth of the market.
Furthermore, rise in mitral valve replacement procedures and adoption of therapeutics is expected to propel the market growth. For instance, anticoagulants are commonly used to manage mitral valve disease and prevent blood clots, which can lead to serious complications such as stroke. Thus, rise in adoption of anticoagulants drives the market growth.
Further, rise in the Incidence of mitral valve diseases can be attributed to several factors, such as aging population and Increase in risk factors such as high blood pressure, diabetes, and obesity. As the population ages, the risk of developing mitral valve disease Increases. This is because the valve can become damaged or weakened over time, making it more prone to malfunction. In addition, the rise in risk factors such as high blood pressure and obesity can Increase the risk of developing mitral valve disease. Moreover, rise in awareness of mitral valve diseases among patients and healthcare professionals has led to earlier diagnosis and treatment, driving demand for medical interventions. Governments around the world are investing in research and development of new treatments for mitral valve disease, which has led to the development of novel therapeutics.
In addition, Increased awareness about the symptoms and risk factors associated with mitral valve disease has led to more people seeking medical treatment for the condition, which has further driven the growth of the market. However, availability of other treatment options for mitral valve disease is expected to restrain the growth of mitral valve disease therapeutics market. There are several alternative treatment options available for mitral valve disease, such as surgical interventions and transcatheter procedures. These alternative options may be preferred by some patients or may be recommended by healthcare providers based on individual patient needs, thus restraining the growth of market.
The global mitral valve disease therapeutics market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into beta blockers, diuretics, anticoagulants, and others. As per age group, the market is categorized into below 55 years and above 55 years. According to distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global mitral valve disease therapeutics market are Zydus Lifesciences Limited, Pfizer Inc., Bayer AG, Novartis AG, Viatris Inc., Alembic Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Limited, and Sanofi.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mitral valve disease therapeutics market analysis from 2022 to 2032 to identify the prevailing mitral valve disease therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the mitral valve disease therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report Includes the analysis of the regional as well as global mitral valve disease therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers
By Drug class
- Beta blockers
- Diuretics
- Anticoagulants
- Others
By Age group
- Below 55 years
- Above 55 years
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Bayer AG
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Viatris Inc.
- Sun Pharmaceutical Industries Limited
- Cipla Ltd
- Zydus Lifesciences Limited
- Sanofi
- Alembic Ltd
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS
CHAPTER 5: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP
CHAPTER 6: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
According to a new report, titled, 'Mitral Valve Disease Therapeutics Market,' The mitral valve disease therapeutics market was valued at $607.74 million in 2022, and is estimated to reach $803.4 million by 2032, growing at a CAGR of 2.8% from 2023 to 2032.The mitral valve disease therapeutics refers to various therapeutic agents used to manage the symptoms and complications of mitral valve disease, which is a condition that affects the mitral valve, a valve located between the heart's left atrium and left ventricle. This valve controls the flow of blood from the atrium to the ventricle and any dysfunction in the valve can cause symptoms such as fatigue, shortness of breath, chest pain, and heart palpitations. The therapeutic agents used to manage mitral valve disease can include medications to manage symptoms and prevent complications, as well as surgical interventions such as valve replacement or repair.
Key factors driving the growth of the mitral valve disease therapeutics market increase in number of people with heart valve disease such as mitral valve, rise in adoption of therapeutics and increasing awareness about available treatment options for mitral valve disease. For instance, according to the American College of Cardiology, more than 5 million Americans are diagnosed with valvular heart diseases (VHD) each year in the U.S. These disorders can cause the valve to malfunction, leading to a range of symptoms and complications. Thus, rise in prevalence of mitral valve diseases has led to the increase in demand for novel therapeutics which drives the growth of the market.
Further, as the global population continues to age, the prevalence of mitral valve disease is expected to increase, leading to a greater demand for effective treatments and therapies. The geriatric population is more prone to developing mitral valve disease owing to age-related degenerative changes in the heart, and this is expected to drive the demand for treatments and therapies for this condition.
In addition, rise in adoption of medication for the management of mitral valve disease can potentially lead to better health outcomes and reduced complications for individuals with the condition. This, in turn, drives the growth of the mitral valve disease therapeutics market. Further, increase in number of heart valve replacement surgeries results in demand of therapeutics. As anticoagulants are prescribed after mechanical heart valve replacement to prevent problems like stroke, thereby driving the growth of market. For instance, an article published by National Library of Medicine 2021, stated that, more than 180,000 heart valve replacement surgeries are performed each year in the U.S., thus rise in number of heart valve replacement surgeries fuels the market growth. Further, the use of medication as a first-line treatment for mitral valve disease is becoming increasingly common, as it can effectively manage symptoms and prevent further damage to the heart.
Furthermore, the growing number of individuals diagnosed with mitral valve disease, coupled with increasing awareness of the importance of adherence to medication, is anticipated to lead to higher demand for drugs that can manage the condition effectively. This, drives pharmaceutical companies to invest more resources into the development of new drugs or improving existing treatments, further contributing to the growth of the market.
The market also offers growth opportunities to the key players in the market. Many developing regions such India and Brazil offer lucrative opportunities to key players of mitral valve disease therapeutics market owing to high population base, increase in demand of novel therapeutics owing to increase in heart valve diseases such as mitral valve and rise healthcare spending.
The mitral valve disease therapeutics market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into beta blockers, diuretics, anticoagulants, and others. On the basis of age group, the market is categorized into below 55 years and above 55 years. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include Zydus Lifesciences Limited, Pfizer Inc., Bayer AG, Novartis AG, Viatris Inc., Alembic Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Limited, and Sanofi.
Key Market Insights (Updated)
- On the basis of drug class, the anticoagulant segment dominated the market in terms of revenue in 2022.
- On the basis of age group, the above 55 years segment dominated the market in terms of revenue in 2022.
- On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period.
- Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Bayer AG
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- Viatris Inc.
- Sun Pharmaceutical Industries Limited
- Cipla Ltd
- Zydus Lifesciences Limited
- Sanofi
- Alembic Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
